ImmunoGen, Inc. (IMGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.81-0.01 (-0.35%)
As of 9:54 AM EDT. Market open.
People also watch:
SGENIMMUINCYEXELARRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open2.81
Prev Close2.82
Bid2.79 x 100
Ask2.80 x 1700
Day's Range2.78 - 2.82
52wk Range2.53 - 14.22
1y Target EstN/A
Market Cap245.39M
P/E Ratio (ttm)-1.69
Beta1.75
Volume83,055
Avg Vol (3m)1,357,087
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube3 days ago

    ETF’s with exposure to ImmunoGen, Inc. : September 23, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to ImmunoGen, Inc. Here are 5 ETF’s with the largest exposure to IMGN-US. Comparing the performance and risk of ImmunoGen, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • ImmunoGen, Inc. :IMGN-US: Earnings Analysis: 2016 By the Numbers : August 31, 2016
    Capital Cube26 days ago

    ImmunoGen, Inc. :IMGN-US: Earnings Analysis: 2016 By the Numbers : August 31, 2016

    Categories: Yahoo Finance Get free summary analysis ImmunoGen, Inc. reports financial results for the year ended June 30, 2016. We analyze the earnings along side the following peers of ImmunoGen, Inc. – Seattle Genetics, Inc., Amgen Inc., Endocyte, Inc., Cerulean Pharma, Inc., Bristol-Myers Squibb Company, Roche Holding Ltd Genusssch., Pfizer Inc., Eli Lilly and Company, Johnson & Johnson ... Read more (Read more...)

  • This Beaten-Down Biotech Could Return 1,500%+: Here’s Why I Won’t Buy It
    Motley Foollast month

    This Beaten-Down Biotech Could Return 1,500%+: Here’s Why I Won’t Buy It

    When the risk outweighs even the best potential growth.